Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 273

Similar articles for PubMed (Select 18333887)

1.

The contribution of ApoB and ApoA1 measurements to cardiovascular risk assessment.

Andrikoula M, McDowell IF.

Diabetes Obes Metab. 2008 Apr;10(4):271-8. doi: 10.1111/j.1463-1326.2007.00714.x. Review.

PMID:
18333887
2.

Non-high-density lipoprotein cholesterol and apolipoprotein B in the prediction of coronary heart disease in men.

Pischon T, Girman CJ, Sacks FM, Rifai N, Stampfer MJ, Rimm EB.

Circulation. 2005 Nov 29;112(22):3375-83.

3.

Is there a better marker of cardiovascular risk than LDL cholesterol? Apolipoproteins B and A-I--new risk factors and targets for therapy.

Walldius G, Jungner I.

Nutr Metab Cardiovasc Dis. 2007 Oct;17(8):565-71. Epub 2007 Jul 16.

PMID:
17631989
4.

Utility of non-high-density lipoprotein cholesterol in hemodialyzed patients.

Schreier L, González AI, Elbert A, Berg G, Wikinski R.

Metabolism. 2004 Aug;53(8):1013-5.

PMID:
15281010
5.
6.
7.

Beyond low-density lipoprotein cholesterol: defining the role of low-density lipoprotein heterogeneity in coronary artery disease.

Mudd JO, Borlaug BA, Johnston PV, Kral BG, Rouf R, Blumenthal RS, Kwiterovich PO Jr.

J Am Coll Cardiol. 2007 Oct 30;50(18):1735-41. Epub 2007 Oct 15.

8.

ApoB/A1 and LDL-C/HDL-C and the prediction of cardiovascular risk in statin-treated patients.

Liem AH, van de Woestijne AP, Roeters van Lennep HW, Zwinderman AH, van der Steeg WA, Jukema JW.

Curr Med Res Opin. 2008 Feb;24(2):359-64.

PMID:
18081989
9.

Lipoprotein predictors of cardiovascular events in statin-treated patients with coronary heart disease. Insights from the Incremental Decrease In End-points Through Aggressive Lipid-lowering Trial (IDEAL).

Holme I, Cater NB, Faergeman O, Kastelein JJ, Olsson AG, Tikkanen MJ, Larsen ML, Lindahl C, Pedersen TR; Incremental Decrease in End-Points Through Aggressive Lipid-Lowering (IDEAL) Study Group.

Ann Med. 2008;40(6):456-64.

PMID:
19160529
11.

Apolipoproteins as markers and managers of coronary risk.

Chan DC, Watts GF.

QJM. 2006 May;99(5):277-87. Epub 2006 Feb 27. Review. Erratum in: QJM. 2006 Nov;99(11):807.

12.

Role of lipid and lipoprotein profiles in risk assessment and therapy.

Ballantyne CM, Hoogeveen RC.

Am Heart J. 2003 Aug;146(2):227-33. Review.

PMID:
12891189
13.
14.

Lipids, apolipoproteins, and their ratios in relation to cardiovascular events with statin treatment.

Kastelein JJ, van der Steeg WA, Holme I, Gaffney M, Cater NB, Barter P, Deedwania P, Olsson AG, Boekholdt SM, Demicco DA, Szarek M, LaRosa JC, Pedersen TR, Grundy SM; TNT Study Group; IDEAL Study Group.

Circulation. 2008 Jun 10;117(23):3002-9. doi: 10.1161/CIRCULATIONAHA.107.713438. Epub 2008 Jun 2.

15.

Concentration of apolipoprotein B is comparable with the apolipoprotein B/apolipoprotein A-I ratio and better than routine clinical lipid measurements in predicting coronary heart disease mortality: findings from a multi-ethnic US population.

Sierra-Johnson J, Fisher RM, Romero-Corral A, Somers VK, Lopez-Jimenez F, Ohrvik J, Walldius G, Hellenius ML, Hamsten A.

Eur Heart J. 2009 Mar;30(6):710-7. doi: 10.1093/eurheartj/ehn347. Epub 2008 Aug 1.

16.

Why is non-high-density lipoprotein cholesterol a better marker of the risk of vascular disease than low-density lipoprotein cholesterol?

Sniderman A, McQueen M, Contois J, Williams K, Furberg CD.

J Clin Lipidol. 2010 May-Jun;4(3):152-5. doi: 10.1016/j.jacl.2010.03.005. Epub 2010 Mar 18. Review.

PMID:
21122647
17.

A meta-analysis of low-density lipoprotein cholesterol, non-high-density lipoprotein cholesterol, and apolipoprotein B as markers of cardiovascular risk.

Sniderman AD, Williams K, Contois JH, Monroe HM, McQueen MJ, de Graaf J, Furberg CD.

Circ Cardiovasc Qual Outcomes. 2011 May;4(3):337-45. doi: 10.1161/CIRCOUTCOMES.110.959247. Epub 2011 Apr 12.

18.

Prognostic utility of apoB/AI, total cholesterol/HDL, non-HDL cholesterol, or hs-CRP as predictors of clinical risk in patients receiving statin therapy after acute coronary syndromes: results from PROVE IT-TIMI 22.

Ray KK, Cannon CP, Cairns R, Morrow DA, Ridker PM, Braunwald E.

Arterioscler Thromb Vasc Biol. 2009 Mar;29(3):424-30. doi: 10.1161/ATVBAHA.108.181735. Epub 2009 Jan 2.

19.

TRL, IDL, and LDL apolipoprotein B-100 and HDL apolipoprotein A-I kinetics as a function of age and menopausal status.

Matthan NR, Jalbert SM, Lamon-Fava S, Dolnikowski GG, Welty FK, Barrett HR, Schaefer EJ, Lichtenstein AH.

Arterioscler Thromb Vasc Biol. 2005 Aug;25(8):1691-6. Epub 2005 Jun 2.

20.

Apolipoprotein B and non-high density lipoprotein cholesterol and the risk of coronary heart disease in Chinese.

Chien KL, Hsu HC, Su TC, Chen MF, Lee YT, Hu FB.

J Lipid Res. 2007 Nov;48(11):2499-505. Epub 2007 Aug 13.

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk